Bellus Health Inc (BLU) is a biopharmaceutical company that focuses on developing treatments for rare diseases. Its lead product candidate, BLU-5937, is being developed for the treatment of chronic cough, a common and debilitating condition that currently has no FDA-approved treatments. The company is also developing other drug candidates for various rare diseases. Bellus Health is headquartered in Laval, Quebec, Canada and is traded on the NASDAQ stock exchange.
Bellus Health Inc (BLU) is a biopharmaceutical company that focuses on developing treatments for rare diseases. Its lead product candidate, BLU-5937, is being developed for the treatment of chronic cough, a common and debilitating condition that currently has no FDA-approved treatments. The company is also developing other drug candidates for various rare diseases. Bellus Health is headquartered in Laval, Quebec, Canada and is traded on the NASDAQ stock exchange.